ArticleLangenbeck's archives of surgery2025
Redirecting venous flow from the superior mesenteric vein to the inferior mesenteric vein in resections for locally advanced pancreatic cancer.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the outcome of ligation of the superior mesenteric vein (SMV) and redirection the venous flow through the inferior mesenteric vein (IMV) in selected patients with pancreatic cancer.
backgroundRadical surgery is the only potentially curable treatment of pancreatic cancer. Tumor-invasion of the SMV and its attributes will in some cases make it impossible to reconstruct the venous flow.
methodsConsecutive patients with pancreatic cancer operated between January 2019 and December 2022 were included. Selected patients eligible for venous flow reversal after systemic chemotherapy were offered surgical exploration.
resultsEleven patients were offered surgery and nine of these went through radical resection with redirection of the venous flow through the IMV. True histological R0 resection was achieved in 6 (67%) patients. No 30- nor 90-days mortality was recorded. Median overall survival was 23.2 ± 11.5 months.
conclusionRedirecting venous flow through the IMV while sacrificing the SMV during pancreatic resection is a safe procedure and may provide the opportunity for curative resection in otherwise unresectable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.